Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Caliper collaborates with DiscoveRx to develop solutions for cell-based GPCR profiling

Caliper Life Sciences : 06 May, 2008  (Company News)
Caliper Life Sciences is collaborating with DiscoveRx to enable functional cell-based G protein-coupled receptor (GPCR) assays from DiscoveRx to be performed on Caliper's LabChip platforms.
The combined offering bundles Caliper LabChip systems with DiscoveRx's cellular assays, including PathHunter Beta Arrestin and cAMP Hunter, to help pharmaceutical and biotechnology researchers discover GPCR drugs more efficiently.

'This collaboration will expand the capability of Caliper's LabChip technology into the dynamic GPCR drug discovery market, an opportunity with substantial potential due to the importance of GPCR drugs and the number of active R and D programmes in neuroscience, cardiovascular, inflammation and other disease areas. Through our collaboration with DiscoveRx, we have expanded our offerings to provide researchers with the ability to prosecute GPCR targets in a functional cellular Assay for lead optimization and profiling,' said Kevin Hrusovsky, chief executive officer of Caliper Life Sciences. 'Caliper's LabChip platform has become the new standard for kinase assays and we have broadened the platform to enable testing of phosphodiesterases, histone deacetylases (including sirtuins) proteases, phophatases and lipid modifying enzymes. The addition of cellular GPCR assays, which are a critical linkage in translational research, expands Caliper's in vitro-in vivo bridge and should provide our customers with enhanced ability to make more informed decisions that ultimately lead to safer and more effective drugs.'

Caliper's LabChip instruments - the LabChip 3000 and LabChip EZ Reader series - which have been adopted by 17 of the top 20 pharmaceutical and biotechnology companies, utilise proprietary microfluidic separation and direct detection of both substrates and products to generate high quality results. This robust, easy-to-use platform, combined with DiscoveRx's innovative Beta-Galactosidase Enzyme Fragment Complementation (EFC) approach for cellular GPCR assays, should provide researchers with the ability to perform more clinically relevant cellular-based assays.

'PathHunter Beta-Arrestin assays, HitHunter cAMP detection and now cAMP Hunter cell lines are all being successfully adopted by leading pharmaceutical companies in their GPCR screening campaigns. Our partnership with Caliper enables the use of these highly successful cell-based GPCR assays on Caliper's microfluidic technology platform to provide a powerful and comprehensive suite of solutions for Caliper's EZ Reader and kinase profiling customers,' said Pyare Khanna, chief executive officer of DiscoveRx. 'Together, we are meeting the demand for GPCR and Kinase lead optimisation and profiling.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo